Angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) affect angiogenesis differently during embryogenesis and tumorigenesis. In an attempt to understand the molecular basis underlying the distinct roles of those two homologous molecules, we investigated the association of Ang-1 and Ang-2 with the extracellular matrix (ECM). TA3 murine mammary carcinoma (TA3) and Lewis lung carcinoma cells expressing v5 epitope-tagged Ang-1 and Ang-2 were used in our studies. The results indicated that Ang-1 is secreted and incorporated into the ECM of the tumor cells, whereas Ang-2 is not associated with the ECM. The mutagenesis study indicated the domain that is responsible for the ECM association of Ang-1 is the linker peptide region between the coiled-coil and the fibrinogen-like domains. A weak binding between the coiled-coil domain of Ang-1 and the ECM was observed. Immunocytochemistry study revealed a distinct ECM distribution pattern of Ang-1, which is quite different from that of fibronectin, laminin, and collagen types I and IV. The ECM-associated Ang-1 proteins are released, and Tie-2 receptors are phosphorylated upon the adhesion of human umbilical vein endothelial cells. Implications of the difference in the ECM association of Ang-1 and Ang-2, which are related to the regulation of angiopoietin activity and their roles in local versus distant angiogenesis during tumor metastasis, are discussed.
angiopoietin families play special roles in angiogenesis due to the restricted expression of their receptors (6 -12) .
Ang-1 and -2 are ϳ70 kDa with a considerable sequence homology, which consists of a signal peptide, an N-terminal coiled-coil domain, a short linker peptide region, and a Cterminal fibrinogen homology domain (FHD) (13, 14) . The coiled-coil region is responsible for dimerization/multimerization of angiopoietins, and the fibrinogen homology domain binds to Tie-2 receptor (15, 16) . Both Ang-1 and Ang-2 form dimers and oligomers (13) (14) (15) 17) .
Angiopoietin-1 and -2 are the unique antagonists. Ang-1 induces tyrosine phosphorylation of Tie-2 receptor and promotes recruitment of the pericytes and smooth muscle cells, thereby playing a role in establishing and maintaining the vascular integrity and quiescence. As an antagonist of Ang-1, Ang-2 competes with Ang-1 for binding of Tie-2, blocks the phosphorylation of Tie-2 receptors induced by Ang-1, and loosens the interactions between endothelial and peri-vascular support cells and ECM (14) .
Targeted disruption of Ang-1 and Tie-2 and overexpression of Ang-2 resulted in embryonic death with the similar vascular defects (7, 14, 18) . Those mice have normal primary vascular development, but the remodeling and maturation of the vasculature are defective (7, 14, 18, 19) . The transgenic mice overexpressing Ang-1 displayed increased vascularization and decreased adult vasculature leakage (20 -22) . Together, those results indicated that Ang-1 plays an indispensable role in the formation of blood vessels during mouse development by recruiting and maintaining peri-endothelial support cells.
Several studies have offered possible mechanisms for the pro-angiogenic effect of Ang-1. Although Ang-1 does not stimulate the proliferation of endothelial cells, it stimulates endothelial cell migration (23) , induces the capillary-like tubule formation, and promotes survival of endothelial cells (24 -28) . Ang-1 inhibits apoptosis of the endothelial cells via phosphatidylinositol 3-kinase/Akt pathway (26, 27) .
Angiogenesis is regulated by the precise balance between pro-and anti-angiogenic factors (4) . Ang-2 expression is often induced in the endothelia undergoing active remodeling or regression and by hypoxia and several growth factors, including VEGF (14, 29 -33) . Ang-2 destabilizes the vasculature. Thus, it initiates angiogenesis in the presence of VEGF, which supplies endothelial cells with necessary survival and proliferation signals (30, 34, 35) , or induces apoptosis of endothelial cells in the absence of the pro-angiogenic factors (36) .
Recent evidence indicates that Ang-1 and -2 are expressed by tumor cells (17, 29) . We found that overexpression of exogenous Ang-2, but not Ang-1, inhibits growth and metastasis of Lewis lung carcinoma (LLC) and TA3 murine mammary carcinoma cells. The tumors overexpressing Ang-2 exhibited aberrant and incomplete angiogenesis in vivo, which is characterized by formation of the disorganized endothelial cell aggregates, the lack of endothelial associated smooth muscle cells, and massive apoptosis of the endothelial cells and surrounding tumor cells (17) . This result is consistent with the notion that Ang-2 inhibits the Ang-1-dependent recruitment of smooth muscle cells.
To reveal the molecular basis underlying the different roles of angiopoietins in tumor angiogenesis, we investigated the relationship between angiopoietins and the ECM in the present study. We found that, unlike Ang-2, Ang-1 is secreted and incorporated into the ECM via its linker peptide region. The association between Ang-1 and the ECM is strong, and the distribution of Ang-1 in the ECM is unique and different from that of fibronectin, laminin, and collagen type I and type IV. The releasing or incorporation of Ang-1 from or into the ECM is regulated by different factors. Tie-2 phosphorylation was detected in HUVECs seeded onto the ECM containing Ang-1, which indicates a regulatory role of the ECM association of Ang-1 in tumor angiogenesis.
Ang-2 expression is regulated by hypoxia and growth factors (29 -33) . Unlike Ang-2, little is known about the regulation of Ang-1 expression. The finding reported herein offers a possible regulatory mechanism for the availability of Ang-1 proteins, that is instead of regulating the production of Ang-1, it may be regulated by its ECM association. The strong ECM binding of Ang-1 implies the effect of Ang-1 is limited to the local environment where it is produced, whereas Ang-2 can diffuse to and affect angiogenesis in the distant sites.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents-Lewis lung carcinoma (LLC, ATCC), TA3 mammary carcinoma (37) cells, and the tumor cell transfectants were maintained as described (17) . Anti-laminin, -fibronectin (Sigma), -collagen types I and IV (Biodesign international), -phosphotyrosine (PY20, Calbiochem), -Tie-2 (C-20, Santa Cruz Biotechnology), -Ang-1 (C-19, Santa Cruz Biotechnology), and -v5 antibodies were used.
Construction of the Expression Vectors-Full-length Ang-1 and Ang-2 cDNAs were generated by RT-PCR as described (17, 40) . The coiled-coil domain and the coiled-coil plus the linker peptide region were generated by RT-PCR using the following pairs of primers. The forward primer for the coiled-coil domain is 5Ј-ACAATGACAGTTTTCCTTTC-CTTT-3Ј and the reverse primer is 5Ј-TGTGTCCATGAGCTCCAGTT-GTTG-3Ј. The coiled-coil plus the linker peptide region was amplified using the same forward primer as that of the coiled-coil domain and a reverse primer, 5Ј-AAATGGTTTCTCTTCTTCTCTTTT-3Ј. The stop codons were omitted from the reverse primers so that the v5 and 6ϫ histidine tags in the pEF6/V5-His expression vector (Invitrogen) can be attached to the C terminus of the Ang-1 fragments. To fuse the FHD of Ang-1 to the signal peptide of Ang-1, we used the full-length Ang-1 in the expression vector (17) as a template and the ExSite PCR-based site-directed mutagenesis kit (Stratagene) together with a forward primer derived from the beginning of the FHD, 5Ј-CGAGACTGTGCA-GATGTATATCAA-3Ј, and a reverse primer derived from the end of the signal peptide, 5Ј-TCTTCTCCCTCCGTTTTCTGGATT-3Ј. The extracellular domain of Tie-2 was obtained by RT-PCR using the following pair of primers. The forward primer is 5Ј-AGTATGGACTCTTTAGCCG-GCTTA-3Ј and the reverse primer is 5Ј-CATCTTTCCCCCTCCGAG-GTCTGC-3Ј. The PCR products were inserted in frame into 5Ј-end of the Fc fragments of human IgG in pEF6/V5-His expression vectors to generate the Tie-2-Fc fusion construct (40) . The authenticity and orientation of the cDNA inserts were confirmed by DNA sequencing.
Transfection-LLC and TA3 carcinoma cells were transfected with the expression constructs containing Ang-1, Ang-2, or the expression vector alone. The transfected cells expressing Ang-1 and Ang-2 were identified as described (17) . COS-7 cells were used in the transient transfection of Ang-1 and -2, the coiled-coil domain, the coiled-coil plus linker region, and the FHD of Ang-1 using LipofectAMINE (Life Technologies, Inc.) as described (17) .
Preparation of the Secreted and the ECM-associated Proteins and Western Blot Analysis-The cell culture supernatants of LLC and TA3 transfectants or the transiently transfected COS-7 cells were collected. The confluent cells layers were released from the culture dishes by incubating with PBS containing 5 mM EDTA. The ECM components remaining on the culture dishes were washed and extracted with 1ϫ SDS Laemmli sample buffer with or without 5% ␤-mercaptoethanol. Western blot analysis was performed as described (17) .
To determine the affinity of the ECM association of Ang-1, the confluent LLC cells expressing Ang-1 were lifted as described. The remaining ECM components were extracted with 0.5 M PBS and 1 M sodium chloride (NaCl) and 0.5 and 1% deoxycholate (DOC) at room temperature for 10 min. The remaining insoluble materials were solubilized by 1ϫ SDS Laemmli sample buffer and subjected to Western blot analysis.
Immuocytochemistry-LLC cells expressing Ang-1 or Ang-2 or transfected with the expression vectors were cultured in 35-mm dishes until subconfluence or confluence. They were fixed with methanol at Ϫ20°C for 15 min. Antibodies against v5 epitope, fibronectin, laminin, type I or IV collagens were used to detected Ang-1v5, Ang-2v5, fibronectin, laminin, types I or IV collagen, respectively, in those fixed cells.
Extraction of the ECM Components and Affinity Purification-The ECM materials derived from the cultured LLC cells were extracted overnight at 4°C in 2 M urea and 0.05 M Tris-HCl (pH 7.4). The soluble materials were dialyzed against PBS and used to coat the enzymelinked immunosorbent assay plates. The ECM derived from the LLC transfectants expressing Ang-1 was extracted in the same way. The ECM extracts containing Ang-1 proteins and the serum-free culture media containing secreted Ang-2, both of which contain v5 and 6ϫ histidine tags at their C-terminal ends, were loaded onto Ni ϩ Probond affinity columns (Invitrogen) and purified following the manufacturer's instructions.
Purified Ang-1v5/His proteins were loaded onto a heparin-Sepharose CL-6B column to test their affinity to heparin. The flow-through fraction was collected, and the column was washed with different concentrations of NaCl from 0.15 to 1 M. The eluted fractions were collected and, along with the flow-through fractions, were subjected to Western blot analysis.
Solid Phase Binding Assay-96-Well enzyme-linked immunosorbent assay plates were coated overnight at 4°C with different ECM components. The components were fibronectin, laminin, type I and IV collagens, Matrigel (20 g/ml, Becton Dickinson), vitronectin (10 g/ml, Sigma), fibrinogen (20 g/ml, Sigma), heparin, chondroitin sulfate, hyaluronic acid (200 g/ml, Sigma), and the whole ECM extracts derived from LLC cells (100 g/ml). The coated plates were washed and blocked with 0.5% bovine serum albumin. The affinity-purified Ang1v5/His and Ang-2v5/His were added into the coated plates (100 ng/ml) for overnight incubation at 4°C. After extensive washing, the bound Ang-1 and Ang-2 were detected. The assays were performed in triplicate.
Tie-2 Tyrosine Phosphorylation Assay-LLC carcinoma cells expressing Ang-1 or Ang-2 were cultured in 100-mm dishes until confluence and were lifted from the dishes as described. The dishes containing the ECM components deposited by the cultured cells were used immediately.
HUVECs (ATCC) were cultured until subconfluence, and switched into the serum-free medium overnight. The cells were then lifted with 0.53 mM EDTA in Hanks' balanced buffer (Life Technologies, Inc.) and washed. 1 ϫ 10 6 HUVECs were seeded onto a plastic dish or one of the ECM-coated dishes freshly generated as described above. They were cultured at 37°C in serum-free medium with or without soluble Ang-1 (200 ng/ml) or Tie-2-Fc fusion proteins (2 g/ml) for 30 min. The cells were then lysed at 4°C with the lysis buffer (50 mM Tris-HCl (pH 7.4), 50 mM NaCl, 1% Triton X-100, 2 mM EDTA, 2 mM sodium orthovanadate, 2 mM sodium fluoride, 2 mM phenylmethylsulfonyl fluoride, 1 mM leupeptin, 1 mM pepstatin A, and 10 g/ml aprotinin). Tie-2 proteins were immunoprecipitated using anti-Tie-2 polyclonal antibody (Santa Cruz Biotechnology). The immunoprecipitated proteins were subjected Western blot analysis using anti-phosphotyrosine antibody (Y20, Calbiochem).
RESULTS

Angiopoietin-1, but Not Angiopoietin-2, Binds to the Extracellular
Matrix-In the process of studying the role of angiopoietins in tumor angiogenesis, we experienced difficulty obtaining the transfected tumor cells that secrete high levels of Ang-1, whereas the transfectants that secrete high levels of Ang-2 were easily obtained. One possible reason for the phenomena is that Ang-1 and Ang-2 may associate with the ECM differently. To investigate that, we generated the stably transfected Lewis lung carcinoma (LLC) and TA3 murine mammary carcinoma (TA3) cells expressing v5 epitope-tagged Ang-1 or Ang-2 ( Fig. 1 , A, a and b). As reported previously (15, 17) , under non-reducing conditions both Ang-1 and Ang-2 tend to aggregate with each other to form dimers and oligomers ( Fig. 1, A and B). The patterns of the aggregation are distinct between Ang-1 and Ang-2. Ang-1 tends to form higher order oligomers (Fig. 1A) , whereas Ang-2 forms dimers, trimers, and oligomers. The molecular weight of the monomer of Ang-1 and Ang-2 is ϳ70 kDa. Because of the C-terminal v5 and 6ϫ histidine epitope tags, Ang-1v5 and Ang-2v5 migrate a little slower.
The aggregation of Ang-1 and Ang-2 is sensitive to the reducing agents, such as ␤-mercaptoethanol. After boiling the protein samples in 1ϫ Laemmli SDS sample buffer containing 5% ␤-mercaptoethanol, the aggregated Ang-1 and Ang-2 are dissociated into monomers (data not shown). It was noted that the amount of the secreted Ang-1 is often lower than that of Ang-2 derived from LLC and TA3 transfectants (Fig. 1A, a and  b) . To examine the possibility that the lack of Ang-1 secretion is due to incorporation of Ang-1 into the ECM of the tumor cells, the transfectants expressing Ang-1 and Ang-2 were grown until confluence, and the cells were then detached from the culture dishes by the EDTA treatment, which is a standard procedure to release cultured cells and leave the ECM components behind on the culture dishes (38) . The remaining ECM components were then extracted from the culture dishes by 1ϫ SDS Laemmli buffer with or without ␤-mercaptoethanol. Western blot analyses were performed using anti-v5 monoclonal antibody to detect v5-tagged Ang-1 or Ang-2. The results indicated that Ang-1 is present in the ECM fraction of the transfected tumor cells, whereas Ang-2 is absent (Fig. 1B) . The ECM-associated Ang-1 is highly aggregated to form oligomers, and no monomer is detected (Fig. 1B, lanes 1 and 2, and 6 and 7) . The aggregated Ang-1 oligomers were dissociated into the monomers by the treatment with ␤-mercaptoethanol (Fig. 1C) , which indicates the role of the cysteine residues in the aggregations. Thus, we have established that Ang-1, but not Ang-2, is incorporated into the ECM of those carcinoma cells.
To confirm that the endogenously expressed Ang-1 is associated with the ECM as the transfected Ang-1, the polyclonal anti-Ang-1 antibody (C19, Santa Cruz Biotechnology) was first purified through an Ang-1v5-conjugated protein A affinity column. The purified antibody was used in Western blot analysis of the ECM components derived from HUVECs. The results indicated that Ang-1 produced by HUVECs is incorporated into the ECM (data not shown). Due to the superior quality of the anti-v5 monoclonal antibody compared with that of the polyclonal anti-Ang-1 antibody, even after the affinity purification (Santa Cruz Biotechnology), most of the following experiments were performed using the transfected tumor cells expressing v5-tagged Ang-1 and Ang-2.
The Biochemical Characters of the ECM-associated Ang-1-The strength of the ECM association of Ang-1 was tested by extracting the cell-free ECM deposited on the culture dishes by LLC cells expressing Ang-1v5 with different concentrations of sodium chloride (NaCl) and deoxycholate (DOC). The insoluble materials after the extractions were solubilized with 1ϫ SDS Laemmli buffer and subjected to Western blot analysis. As shown in Fig. 2 , most of the ECM-incorporated Ang-1 resisted 0.15 M NaCl extraction (Fig. 2, lane 2) ; a fair amount of Ang-1 remains in the ECM after 1 M NaCl extraction (Fig. 2, lane 4) , and a fraction of Ang-1 is in the ECM fraction even after 1% DOC extraction (Fig. 2, lane 6 ), which indicated a strong ECM association and implicated a gradual assembly process of Ang-1 into the ECM (Fig. 2) .
The Binding Affinity of Ang-1 to Different ECM Components-The C terminus of Ang-1 shares the sequence homology with fibrinogen, which binds to heparin. To investigate whether Ang-1 binds to the ECM via its interaction with the sulfated glycosaminoglycans, the purified Ang-1v5/His (Fig.  3A, lane 1 ) was applied to a heparin-Sepharose CL-6B affinity column (Amersham Pharmacia Biotech). The unbound flowthrough was collected, and the column was washed with 0.15, 0.3, 0.5, 1 M NaCl (Fig. 3A, lanes 3-6) . The eluted fractions were collected, and along with the flow-through fraction, they were subjected to the Western blot analysis by using anti-v5 monoclonal antibody to detect the presence of Ang-1v5/His in each fraction. The results indicated that Ang-1v5/His does not bind to the heparin affinity column and was fully recovered in the flow-through fraction (Fig. 3A, lane 2) . To confirm the above finding and avoid the possibility that the purified soluble Ang1v5/His may be modified and different from the ECM-associ- The expression of Ang-1 and Ang-2 in the serum-free conditioned media (A) and in the ECM (B) by the transfected LLC and TA3 cells were determined by Western blot analyses using anti-v5 antibody (Invitrogen). The Western blot analyses were performed under non-reducing conditions using the concentrated serum-free media (A) or the ECM extracts (B) derived from two independent isolates of the transfected LLC cells expressing Ang-1v5 (A, a,  lanes 1 and 2, and B, lanes 1 and 2) or Ang-2v5 (A, a, lanes 3 and 4, B, and lanes  3 and 4) ; two independent isolates of the transfected TA3 cells expressing Ang-1v5 (A, b, lanes 1 and 2, B, lanes 6 and 7) or Ang-2v5 (A, b, lanes 3 and 4, B, lanes 8  and 9) , and the tumor cells ated Ang-1 and thereby unable to bind to heparin, soluble sulfated glycosaminoglycans, heparin, and chondroitin sulfate (200 g/ml) were added into serum-free cell culture medium (SFM) of LLC carcinoma cells expressing Ang-1. After 2, 12, and 24 h of incubation, the SFM and ECM fractions were collected and analyzed. The Western blot results indicated that neither heparin nor chondroitin sulfate releases Ang-1 from the ECM of the transfected LLC cells (Fig. 3B , and data not shown).
In an attempt to identify the ECM component(s) that bind(s) to Ang-1, solid phase binding assays were performed to assess the binding affinity of Ang-1 to several ECM components. The assays were performed in triplicate, and the results are listed in the Fig. 4 . The purified Ang-1v5 binds to whole ECM extracts derived from LLC carcinoma cells with high affinity (Fig.  4, column 8) . The weak bindings to Matrigel, fibrinogen, and vitronectin were observed, which can't account entirely for the high affinity binding between Ang-1 and the ECM extracts. Ang-1 displayed no affinity to fibronectin, laminin, collagen type I and type IV, heparin, chondroitin sulfate, and hyaluronic acid (Fig. 4) . This result offered the possibility that Ang-1 binds to the ECM via an unidentified ECM protein(s).
Immunocytochemistry Studies Revealed a Distinct ECM Distribution Pattern of Angiopoietin-1-The distribution patterns of Ang-1 and Ang-2 were investigated and compared with fibronectin, laminin, and type I and IV collagens by performing immunocytochemistry on LLC carcinoma cells expressing Ang1v5 or Ang-2v5 using anti-v5 antibody or antibodies against the appropriate ECM proteins. The cell-free ECM deposited by LLC cells expressing Ang-1 or Ang-2 was also examined. The immunocytochemistry studies uncovered a distinct Ang-1 distribution pattern in the ECM of LLC carcinoma cells, which is different from the distribution of fibronectin, laminin, and types I and IV collagen (Fig. 5, A and B) . Ang-1 is incorporated into the ECM as small granule-like depositions, which are more or less evenly distributed beneath the cells (Fig. 5A, a and b) . Some cell-free spaces, which are left behind by the migrating cells, are positive for the similar Ang-1 depositions (Fig. 5A, a,  arrow) . The distribution pattern of Ang-1 was preserved even after the cells were lifted by the treatment of EDTA (Fig. 5A, b) , which indicated that instead of loosely binding to the tumor cells, those Ang-1 proteins are incorporated into the ECM of the tumor cells. On the contrary, there is no trace of Ang-2 in the cell-free ECM deposited by the cells expressing Ang-2 (Fig. 5A,  d ). Ang-2 was only detected in the cytoplasm of the transfected cells, which presumably reflects the presence of Ang-2 in the secretory pathway of the cells (Fig. 5A, c, arrowheads) .
Angiopoietin-1 Is Released in the Response to Phorbol 12-Myristate 13-Acetate (PMA)-
The association of Ang-1 with the ECM of tumor cells led us to explore the regulatory mechanisms of its incorporation and releasing, which may modulate its activity. The confluent LLC carcinoma cells expressing Ang-1 were cultured overnight in the presence of different growth factors or PMA in serum-free cell culture medium. After releasing the cells from the culture dishes, the remaining ECM components were extracted with 1ϫ SDS Laemmli buffer and subjected to Western blot analysis using anti-v5 antibody. The results indicated that PMA stimulates the releasing of the ECM-associated Ang-1 (Fig. 6, lane 2) . Transforming growth factor-␤1 (TGF-␤1) promotes slightly the incorporation of Ang-1 into the ECM, which may reflect the positive effect of TGF-␤1 on synthesis of the ECM components (39) (Fig. 6, lane 3) .
The ECM-associated Ang-1 Does Not Bind to Tie-2-Fc Fusion Protein-To determine whether the ECM-associated Ang-1 proteins bind to Tie-2-Fc fusion proteins, the confluent LLC cells expressing Ang-1 or the ECM deposited by the LLC cells expressing Ang-1 were fixed and incubated with anti-v5 antibody or the purified Tie-2-Fc fusion proteins. Anti-v5 antibody and FITC-conjugated rabbit anti-mouse antibody (Sigma) revealed that many Ang-1 proteins were deposited into the ECM of the tumor cells (Fig. 7B, a and b) ; however, Ang-1 proteins in the ECM exhibited no affinity to Tie-2-Fc fusion proteins (Fig.  7B, c and d) . In order to eliminate the possibility that the fixation procedure could affect the binding between the ECMassociated Ang-1 and Tie-2-Fc fusion protein, Tie-2-Fc fusion proteins were directly added into the cultured LLC carcinoma cells expressing Ang-1 or into the ECM freshly derived from the LLC cells expressing Ang-1. No binding was detected in both cases (data not shown). Those ECM-associated Ang-1 proteins were extracted by 2 M urea/Tris-HCl buffer (pH 7.4), dialyzed in PBS, and immunoprecipitated using Tie-2-Fc fusion proteins and protein A beads. The precipitated proteins were subjected to Western blot analysis using anti-v5 antibody. Ang-1 proteins were found to be precipitated by Tie-2-Fc fusion proteins (Fig.  7A, lane 2) . Together, those results suggested that after their secretion from the tumor cells, Ang-1 proteins are incorporated into the ECM, and their Tie-2-binding sites are no longer accessible; upon the release from the ECM, the solubilized Ang-1 proteins regained their ability to bind to Tie-2. Under physiologic conditions, this may serve as an efficient regulatory mechanism for Ang-1 activity.
Tie-2 Phosphorylation Is Achieved by Adhering HUVECs to the ECM Containing Ang-1 Proteins-To study whether the ECM-associated Ang-1 plays a role in angiogenesis, the ability of the ECM-associated Ang-1 to promote Tie-2 receptor phosphorylation was evaluated using HUVECs. The subconfluent HUVECs were serum-starved for about 14 h and then lifted from the culture dishes. 1 ϫ 10 6 cells were seeded onto a plastic culture dish with (Fig. 8, lane 3) or without (Fig. 8, lane 1) purified soluble Ang-1 (200 ng/ml) or the culture dish containing the ECM components deposited by the confluent LLC cells expressing Ang-1 (Fig. 8, lane 4) or Ang-2 (Fig. 8, lane 2) . The HUVECs were incubated on those cell culture dishes for 30 min and then lysed at 4°C with the lysis buffer. The amount of the Tie-2 proteins in the lysates was determined by Western blot analysis of 50 g of proteins from each lysate using anti-Tie-2 antibody (C-20, Santa Cruz Biotechnology, Fig. 8B ). The re- FIG. 2 . The ECM association of angiopoietin-1. The Ang-1-containing ECM was extracted at room temperature for 10 min with 0.15, 0.5, and 1 M NaCl and 0.5 and 1% DOC, respectively. The insoluble ECM components were then extracted with 1ϫ SDS Laemmli buffer and subjected to Western blot analysis using anti-v5 antibody ( lanes  2-6, respectively) . The proteins in the lane 1 were derived from the ECM without prior extraction with any reagents. Lanes 7 and 8 are the ECM extracts derived from LLC cells expressing Ang-2 or transfected with the expression vector alone, respectively. The molecular mass markers are as indicated.
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sults indicated that the endothelial cells used in the experiments express a similar amount of Tie-2 receptors (Fig. 8B) . The phosphorylated Tie-2 proteins in the lysates were assessed by performing immunoprecipitation using anti-Tie-2 polyclonal antibody (C-20, Santa Cruz Biotechnology) and analyzing the precipitated proteins on Western blot using anti-phosphotyrosine antibody (Y20, Calbiochem). The results indicated that Tie-2 receptors on HUVECs are phosphorylated by Ang-1 derived from the ECM, and the phosphorylation is inhibited by the addition of the excess amount of Tie-2-Fc fusion proteins (2 g, Fig. 8, lane 5) .
To assess whether HUVECs release Ang-1 proteins from the ECM, HUVECs cells (1 ϫ 10 6 cells/100-mm dish) or the serumfree culture media (SFM) alone were placed on the ECM deposited by LLC cells expressing Ang-1 for 30 min. The cell culture dishes with or without HUVECs were treated with 5 mM EDTA in PBS for 5 min to release the adhering cells. The remaining ECM materials on the culture dishes were extracted and subjected to Western blot analysis, and the results indicated that the reduced amount of Ang-1 is retained in the ECM after the adhesion of HUVECs compared with that retained in the ECM incubated with SFM alone (data not shown). Thus, HUVECs promote the release of Ang-1 from the ECM.
The Domain That Mediates the ECM Binding of Ang-1 Is Mapped to Its Linker Peptide
Region-To determine which domain of Ang-1 mediates its ECM association, several expression constructs were made as indicated in Fig. 9A . They were the coiled-coil domain, the coiled-coil plus linker peptide region, and the FHD of Ang-1. The cDNA sequence encoding the signal peptide of Ang-1 was constructed into the N terminus of the above cDNA fragments so those fragments can be secreted properly (Fig. 9A) . The full-length Ang-1 and -2 and the fragments of Ang-1, which contain C-terminal v5 epitope tags, were used to transfect COS-7 cells. 72 h after the transient transfection, the cell culture supernatants and the ECM materials derived from the transfected cells were either collected or extracted from the cell culture dishes and subjected to Western blot analyses using anti-v5 antibody to determine the distribution patterns of Ang-1, Ang-2, and the different fragments of Ang-1. The results indicated that the linker peptide region of Ang-1 between the coiled-coil and the fibrinogen-like domains, which contains 27 amino acids, is mainly responsible for the ECM association of Ang-1 (Fig. 9, B and C, lanes 5 and 6) . A weak interaction between the coiled-coil domain of Ang-1 and the ECM was also detected (Fig. 9, B and C, lanes 7 and 8) .
To investigate whether the ECM binding domain in the linker peptide region of Ang-1 is also present in Ang-2, we first compared the sequence homology between the domains of Ang-1 and Ang-2. We found that the percentages of the identical amino acids are 59, 19, and 64%, respectively, in the coiled-coil domain, the linker peptide region, and the fibrinogen-like domains of Ang-1 and Ang-2. No significant homology in the linker peptide region implied that the ECM binding domain in this region of Ang-1 is likely absent in the Ang-2 molecule.
To confirm that the absence of the ECM binding of Ang-2 is due to the lack of the ECM-binding site(s) in the molecule, but not the blockage of the binding site(s) by possible steric restraints in the full-length Ang-2 molecule, we made three additional deletions of Ang-2, which are similar to those of Ang-1 deletions (Fig. 9A) . They are the coiled-coil domain, the coiled- FIG. 3. Ang-1 does not bind to heparin. A, the purified v5-tagged Ang-1 proteins (500 ng/ml) were loaded onto a heparin-Sepharose CL-6B affinity column. The flow-through was collected, and the column was washed with 0.15, 0.3, 0.5, and 1 M sodium chloride (NaCl, A, lanes 3-6) , and the eluted proteins were collected. All the collected fractions were subjected to Western blot analysis using anti-v5 antibody. The results indicated that Ang-1v5 does not bind to heparin-Sepharose, and all the v5-tagged Ang-1 was in the flow-through fraction (A, lane 2) . Lane 1 in A represents the starting materials. B, the ECM proteins were extracted, and Western blot analysis was performed after the incubation of the confluent LLC cells expressing Ang-1 with serum-free cell culture media containing heparin (200 g/ml, B, lane 2), chondroitin sulfate (200 g/ml, B, lane 3) , or SFM alone (B, lane 1) for 12 h. Molecular mass markers are as indicated.
FIG. 4. Binding of Ang-1 to the different ECM components.
The binding affinities of Ang-1 to several different ECM components were determined in the solid phase binding assays. Ang-1 exhibited no affinity to fibronectin, laminin, collagen types I and IV (columns 1-4, respectively), heparin, chondroitin sulfate, and hyaluronic acid (columns 10 and 12, respectively). The weak affinities of Ang-1 to vitronectin and fibrinogen were observed (columns 5 and 6). Ang-1 displayed a moderate affinity to Matrigel (column 7) and a strong affinity to the 2 M urea ECM extracts derived from LLC carcinoma cells (column 8). All the experiments were performed in triplicate.
coil plus the linker peptide region, and the fibrinogen-like domain of Ang-2. All the deletion constructs contain the Nterminal signal peptides of Ang-2 for their proper expression and secretion and the C-terminal v5 epitope tags derived from the pEF/6/v5-His expression vectors for their detection. After confirming the authenticities of the expression constructs by DNA sequencing, they were used to transfect COS-7 cells. After the transient transfection, the distributions of Ang-2 fragments in the cell culture media and the ECM fractions were examined by Western blot analysis. Our results indicated that all three fragments of Ang-2, the coiled-coil domain, the coiled-coil plus the linker peptide region, and the fibrinogen-like domain, are secreted as the full-length Ang-2; none of them associates with the ECM of the transfected COS-7 (data not shown). This result indicated clearly that unlike Ang-1, Ang-2 does not contain the ECM binding domain.
DISCUSSION
Studies have shown that angiopoietin-1 and -2 are unique antagonists. Ang-2 blocks tyrosine phosphorylation of Tie-2 induced by Ang-1 and disrupts angiogenesis in vivo (14) . Our previous study (17) showed that Ang-1 and -2 play different roles in tumor angiogenesis. Ang-2 inhibits tumor angiogenesis by blocking recruitment of smooth muscle cells to the newly formed blood vessels and causing apoptosis to the endothelial cells (17) .
Functional Significance of the ECM Association of Ang-1-In this study, we examined the potential relationship of Ang-1 and -2 with the ECM, which is known to modulate activities of many growth factors, including VEGF and bFGF (41, 42) . Our results indicated that unlike Ang-2, Ang-1 is secreted and incorporated into and sequestered by the ECM. The different ECM association capacity enables those two antagonists to regulate local and distant angiogenesis differently. Ang-1 is most likely to regulate angiogenesis in the vicinity of its secretion sites, whereas Ang-2 is likely to diffuse through interstitial tissues and blood vessels to the distant organs.
The ability to distribute Ang-1 and -2 to local environment and/or distant sites may play an important role in regulating tumor dormancy in some situations (43) (44) (45) . Both Ang-1 and -2 are expressed by endothelial and tumor cells (17, 29) . During the growth of primary tumors, balanced expression of local Ang-1 and -2 and expression of other pro-angiogenic factors, such as VEGF, may ensure tumor angiogenesis and growth in the primary sites. When Tie-2 receptors on local endothelial cells are saturated, it is likely that the excess amount of Ang-1 produced by the primary tumors would be incorporated into and sequestered by the surrounding ECM, whereas the excessive amount of Ang-2 may diffuse to distant organs. The micrometastases seeded and developed in the distant organs, such as lung and liver, have microenvironments that contain pro-and anti-angiogenic factors produced by local micrometastatic tumors and surrounding host stromal tissues and are more or less similar to the microenvironments of primary tumors. However, on top of the microenvironments, Ang-2, not Ang-1, produced by the predominant primary tumors, which is , respectively, for 14 h, the cells were released from the cell culture dishes by the treatment of EDTA, and the remaining ECM components were extracted with 1ϫ SDS Laemmli buffer and subjected to the Western blot analysis using anti-v5 antibody. Molecular mass markers are as indicated.
Angiopoietin-1 Binds to the Extracellular Matrix
stable and has a long half-life (data not shown), could travel to the distant organs and change the balance in favor of inhibiting tumor angiogenesis, which may contribute to the dormancy observed in some secondary tumors. More detailed studies are required to confirm this hypothesis.
The ECM Association of Ang-1 Provides a Different Regulatory Mechanism for the Availability of Ang-1-Ang-1 is wildly expressed both in embryo and in adult and exhibits a more uniform expression pattern compared with that of Ang-2 (13, 14). Ang-2 has a wild expression pattern in embryo. However, in adult tissues, its expression is restricted in the tissues where vascular remodeling is ongoing, such as ovary, uterus, and placenta (14) . Ang-2 is up-regulated by hypoxia and several different cytokines including VEGF and tumor necrosis factor-␣ (31-33), whereas the expression of Ang-1 is not affected.
The association of Ang-1 with the ECM reported herein offered a different type of regulation of the availability of Ang-1. Instead of regulating its production, as Ang-2, free Biotechnology, B) . The rest of the proteins were used in the immunoprecipitation using anti-Tie-2 antibody (Santa Cruz Biotechnology). The immunoprecipitated proteins were subjected to Western blot analysis using anti-phosphotyrosine (A). Molecular mass markers are as indicated.
Ang-1 in microenvironment can be regulated by changing its ECM association status. The factors that promote or inhibit its ECM incorporation or releasing affect the interaction between Ang-1 and Tie-2 receptor, sequential signal transduction, and angiogenesis. This type of regulation provides a quicker response to the changes in the microenvironment without the requirement of mRNA and proteins syntheses. It is well established that the activities of some growth factors are regulated in that way, including TGF-␤ (39) .
The Biochemical Characters of the ECM Association of Ang-1-An extensive effort was made to try to identify the ECM component(s) that mediate(s) the ECM association of Ang-1. Matrigel, fibrinogen, and to a less extent vitronectin exhibited weak affinities to Ang-1, which is much lower than that of unpurified ECM extracts derived from LLC cells and cannot account entirely for the ECM association of Ang-1 (Fig. 4) . The immunocytochemistry studies indicated that the ECM distribution pattern of Ang-1 is unique and unlike that of fibronectin, laminin, and collagen types I and IV (Fig. 5) .
To determine the effect of the ECM association on the function of Ang-1, we assessed whether Tie-2-Fc fusion protein binds to the ECM-associated Ang-1. The result indicated that the ECM-associated Ang-1 is not accessible for Tie-2, and the ECM serves as a storage and sequestration site for Ang-1. The incubation of HUVECs on the ECM containing Ang-1 induced the release of Ang-1 from the ECM and tyrosine phosphorylation of Tie-2, which indicated that HUVECs cells are able to respond to Ang-1 originally sequestered in the ECM (Fig. 8) . This may reflect the in vivo situations and indicate that activity of Ang-1 is restricted in local environment and regulated more tightly than that of Ang-2.
The Domain of Ang-1 That Mediates Its ECM Association Is the Linker Peptide Region-The deletion analysis indicated that the linker peptide region of Ang-1 between the coiled-coil domain and the FHD mediates the ECM association of Ang-1 (Fig. 9) . The identification of the ECM association domain of Ang-1 will allow us to study the importance of the ECM association on Ang-1 function in the future.
In summary, we have discovered that Ang-1 is incorporated into the ECM after its secretion, whereas Ang-2 is secreted and does not associate with the ECM. The domain that mediates the ECM association of Ang-1 is mapped to the linker peptide region between the coiled-coil and the fibrinogen homology domains. The different ECM association capacity of Ang-1 and Ang-2 offers a possible mechanism for the distinct regulations of local and distant tumor angiogenesis by two antagonistic factors. FIG. 9 . The linker peptide region of Ang-1 is responsible for its ECM association. Several cDNA expression constructs were made including the fulllength of Ang-1 or Ang-2, the coiled-coil region, the coiled-coil plus the linker peptide region, the fibrinogen-like region of Ang-1 (A). All the Ang-1 fragments contain N-terminal signal peptides of Ang-1 and the C-terminal v5 epitope tags. These expression constructs were used to transfect COS-7 cells transiently. 72 h after the transfection, the cell culture supernatants (B) and the ECM proteins (C) were collected or extracted and subjected to Western blot analyses to determine the distribution of Ang-1, Ang-2, and the Ang-1 fragments using anti-v5 antibody. Lanes 1 and 2, full-length Ang-1; lanes 3 and 4, full-length Ang-2; lanes 5 and 6, the coiled-coil domain plus the linker peptide region of Ang-1; lanes 7 and 8, the coiled and coil region of Ang-1; lanes 9 and 10, the fibrinogen homology domain of Ang-1; lane 11, COS-7 cells transfected with the expression vector alone. Molecular mass markers are as indicated.
